Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Injection Site Tolerability
Secondary Objective:
- To assess the safety profile of alirocumab SAR236553 (REGN727)
- To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553
(REGN727)